Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of gene marker in diagnosing ischemic cardiomyopathy

A technology of ischemic cardiomyopathy and genes, applied in the field of biomedicine, can solve the problems of different incidence rates of coronary heart disease and CHD

Inactive Publication Date: 2019-03-19
THE THIRD HOSPITAL OF HEBEI MEDICAL UNIV
View PDF2 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] Coronary atherosclerosis is the result of the interaction of multiple risk factors. There are many risk factors such as blood lipids, abnormal blood sugar metabolism, and high blood pressure. However, some studies have found that even if the risk factors are well controlled, there are differences in the incidence of CHD
In addition, the incidence of coronary heart disease in different races is also different. It can be seen that traditional cardiovascular risk factors cannot fully explain the incidence of CHD, which may be related to individual genetic background
At present, there are few studies on the incidence and treatment of coronary heart disease from the perspective of genes. Therefore, it is urgent to find a sensitive and effective biological marker for the detection of high-risk individuals of coronary heart disease, so as to effectively carry out early warning and prevention of coronary heart disease. Potential Value of Exploring New Approaches to Treat Ischemic Cardiomyopathy From a Genetic Perspective

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of gene marker in diagnosing ischemic cardiomyopathy

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0071] Example 1 Screening for Gene Markers Related to Ischemic Cardiomyopathy

[0072] 1. Sample collection

[0073] 1) Collection of blood samples

[0074] Blood samples from 25 normal people and patients with ischemic cardiomyopathy were collected, and the EDTA anticoagulant tubes were allowed to stand for 10 minutes, then the serum was separated by centrifugation, and stored at -20°C for later use.

[0075] 2) Collection of tissue samples

[0076] Left ventricular tissue samples were collected from 25 patients with ischemic cardiomyopathy and from 10 non-cardiomyopathy deaths.

[0077] Inclusion criteria for patients with ischemic cardiomyopathy: refer to Burch's (1972) diagnostic criteria for ICM and the New York Heart Association (NYHA) cardiac function classification criteria to determine: (1) have a clear history of coronary heart disease (angina pectoris) , myocardial infarction more than half a year, electrocardiogram and enzyme abnormalities) evidence; (2) obviou...

Embodiment 2

[0090] Example 2 QPCR sequencing to verify the differential expression of TMEM30B gene

[0091] 1. According to the detection results of high-throughput sequencing, the TMEM30B gene was selected for large-sample QPCR verification.

[0092] 2. RNA extraction

[0093] Use QIAGEN's tissue RNA extraction kit to extract total RNA, and blood RNA extraction kit to extract blood RNA. For specific steps, refer to the instruction manual.

[0094] 3. Reverse transcription:

[0095] 1) Add dNTP mixture 1μl, Oligo dT primer 1μl, total RNA 2μg, add RNase FreeddH 2 O Make the total volume to 10 μl, carry out denaturation and annealing reaction on the PCR instrument, 65°C, 5min, place at 4°C after the reaction is completed.

[0096] 2) Construct a 20 μl reaction system, continue to add 4 μl of 5×Primer Script Buffer, 0.5 μl of RNase Inhibitor, 0.5 μl of Prime Script RTase, RNase Free ddH 2 O 5.0 μl, carry out the reverse transcription reaction on the PCR instrument according to the follow...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses an application of a gene marker in diagnosing ischemic cardiomyopathy. The gene marker is TMEM30B. Expression of the TMEM30B in a patient with cardiomyopathy is up-regulated, and early assisted diagnosis can be provided for the patient with cardiomyopathy by detecting the expression level of a TMEM30B gene, so that early intervention and treatment are achieved, and the survival rate and the life quality of the patient are improved.

Description

technical field [0001] The invention relates to the field of biomedicine, and relates to the application of gene markers in the diagnosis of ischemic cardiomyopathy, and the specific gene marker involved is TMEM30B. Background technique [0002] Coronary atherosclerotic heart disease (CAHD) is a heart disease caused by atherosclerosis in the coronary arteries causing stenosis or occlusion of the lumen, resulting in myocardial ischemia, hypoxia or necrosis, referred to as coronary heart disease. disease, CHD), also known as ischemic heart disease (ischemic heart disease, IHD). Coronary heart disease is the most common and serious type of organ lesions caused by atherosclerosis. It is one of the common diseases that affect human health and quality of life, and it is also one of the diseases with the highest morbidity and mortality worldwide. Relevant data shows: It is estimated that by 2030, the death toll of coronary heart disease will account for 13.1% of the total death to...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C12Q1/6883G01N33/68
CPCC12Q1/6883C12Q2600/136C12Q2600/158G01N33/6893G01N2333/4739G01N2800/325G01N2800/50
Inventor 李海滨曹海育
Owner THE THIRD HOSPITAL OF HEBEI MEDICAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com